Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Roddie

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Biology|November 24, 2023
The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular ImmunotherapeuticsVedika Mehra, Jyoti Bikram Chhetri, Samira Ali, et al.
Frontiers in Immunology|August 28, 2020
Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell TransplantationManar S Shafat, Vedika Mehra, Karl S Peggs, et al.
The Lancet. Haematology|November 7, 2024
Accelerating and optimising CAR T-cell manufacture to deliver better patient productsGiulia Agliardi, Juliana Dias, Alexandros Rampotas, et al.
Cancers|March 28, 2024
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based ImmunotherapyAngela Hwang, Vedika Mehra, Jyoti Chhetri, et al.
Immunotherapy|June 19, 2026
CAR cellular therapies for acute myeloid leukemia: current landscape and future directionsJure Hederih, James Patrick, Isaac Gannon, et al.
Cytotherapy|January 28, 2019
Manufacturing chimeric antigen receptor T cells: issues and challengesClaire Roddie, Maeve O'Reilly, Juliana Dias Alves Pinto, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 4, 2025
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapyFrederick W Vonberg, Imran Malik, Maeve O'Reilly, et al.
Cancers|March 28, 2026
Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular TherapiesIsmini Tsagkaraki, Isaac Gannon, Alexandros Rampotas, et al.
JACC. Cardiooncology|August 16, 2021
CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?Arjun K Ghosh, Daniel H Chen, Avirup Guha, et al.
The Lancet. Infectious Diseases|February 4, 2024
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literatureKathleen P L Cheok, Adrian Farrow, Deborah Springell, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Biology|November 24, 2023
The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular ImmunotherapeuticsVedika Mehra, Jyoti Bikram Chhetri, Samira Ali, et al.
Frontiers in Immunology|August 28, 2020
Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell TransplantationManar S Shafat, Vedika Mehra, Karl S Peggs, et al.
The Lancet. Haematology|November 7, 2024
Accelerating and optimising CAR T-cell manufacture to deliver better patient productsGiulia Agliardi, Juliana Dias, Alexandros Rampotas, et al.
Cancers|March 28, 2024
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based ImmunotherapyAngela Hwang, Vedika Mehra, Jyoti Chhetri, et al.
Immunotherapy|June 19, 2026
CAR cellular therapies for acute myeloid leukemia: current landscape and future directionsJure Hederih, James Patrick, Isaac Gannon, et al.
Cytotherapy|January 28, 2019
Manufacturing chimeric antigen receptor T cells: issues and challengesClaire Roddie, Maeve O'Reilly, Juliana Dias Alves Pinto, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 4, 2025
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapyFrederick W Vonberg, Imran Malik, Maeve O'Reilly, et al.
Cancers|March 28, 2026
Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular TherapiesIsmini Tsagkaraki, Isaac Gannon, Alexandros Rampotas, et al.
JACC. Cardiooncology|August 16, 2021
CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?Arjun K Ghosh, Daniel H Chen, Avirup Guha, et al.
The Lancet. Infectious Diseases|February 4, 2024
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literatureKathleen P L Cheok, Adrian Farrow, Deborah Springell, et al.
Pageof 7